Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qianhai Health HoldingsHKSE:00911 +14.29%39 EBITDA Margin % is 0.35% as of Dec. 2025, which is 44% below its 10-year median of 0.63. GuruFocus rates HKSE:00911 with a GF Score™ of 39/100 and a GF Value™ of HK$0.22 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 957 Drug Manufacturers companies, Qianhai Health Holdings ranks worse than 73.67% on this metric.
Qianhai Health Holdings (HKSE:00911) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Qianhai Health Holdings EBITDA Margin % Related Terms
Qianhai Health Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Qianhai Health Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qianhai Health Holdings EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Qianhai Health Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Qianhai Health Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qianhai Health Holdings (HKSE:00911) has a EBITDA Margin % of 0.35% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qianhai Health Holdings and its competitors. This is 44% below median its historical median of 0.63. According to the industry distribution chart, Qianhai Health Holdings ranks #705 out of 957 companies in the Drug Manufacturers industry, placing it in the top 73.7%.
Is Qianhai Health Holdings' EBITDA Margin % too high?
Qianhai Health Holdings' current EBITDA Margin % of 0.35% is 44% below median its 10-year median of 0.63. The Drug Manufacturers industry median EBITDA Margin % is 12.01. Qianhai Health Holdings' value of 0.35% is 97.1% below this industry median. Based on the distribution chart, Qianhai Health Holdings ranks #705 out of 957 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Qianhai Health Holdings has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qianhai Health Holdings' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Qianhai Health Holdings ranks #705 out of 957 companies for EBITDA Margin %. This places Qianhai Health Holdings in the lower half of its industry. The industry median EBITDA Margin % is 12.01. Qianhai Health Holdings' value of 0.35% is 97.1% below this benchmark. While the company's 10-year median is 0.63 vs. the industry median of 12.01, Qianhai Health Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.01, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qianhai Health Holdings's current EBITDA Margin % of 0.35% is 97.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qianhai Health Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qianhai Health Holdings's current EBITDA Margin % is 0.35%, which is 44% below median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qianhai Health Holdings stock overvalued right now?
Based on GuruFocus' analysis, Qianhai Health Holdings (HKSE:00911) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.22, compared to a current price of HK$0.60 — trading 172.7% above its estimated fair value. The current EBITDA Margin % is 0.35%, which is 44% below median its 10-year median of 0.63 and 97.1% below the Drug Manufacturers industry median of 12.01. Qianhai Health Holdings' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Qianhai Health Holdings (HKSE:00911), the current EBITDA Margin % is 0.35% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qianhai Health Holdings (HKSE:00911) Overvalued in 2026?
Based on GuruFocus' analysis, Qianhai Health Holdings stock appears to be overvalued.
The current stock price of HK$0.60 is trading 172.7% above its estimated GF Value™ of HK$0.22.
GuruFocus considers Qianhai Health Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:00911:
EBITDA Margin %: 0.35% (44% below median its 10-year median of 0.63)
GF Value™: HK$0.22 vs. price of HK$0.60 (172.7% above fair value)
Industry Position: 97.1% below the Drug Manufacturers median (#705 of 957)
No single metric tells the full story. See the HKSE:00911 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qianhai Health Holdings Ltd principally engaged in the sale of health products and electronic component products. It includes Chinese herbal medicines, skin-care and other healthcare products, and the sale of information technology components. The operating segments of the group are Healthcare products and Electronic component products. Healthcare products include the sale of healthcare products, including Chinese herbal medicines, skincare, and other healthcare products. Electronic component products include the sale of information technology components products including central processing units and semiconductors. The group's revenue is all derived from Hong Kong.
39GF Score
Get the complete analysis for HKSE:00911
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00911 has been successfully added to your 
